NCT03986086View on ClinicalTrials.gov

MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

PHASE1/PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

September 30, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2023

Conditions

Hematologic Malignancy

Interventions

DRUG

MPH966

RP2D tablet

DRUG

Placebo

MPH966 placebo table

Trial Locations (1)

27705

Duke University Adult Bone Marrow Transplant Clinic, Durham

Sponsors

Collaborators (1)

Mereo BioPharma

All Listed Sponsors

collaborator

Mereo BioPharma

INDUSTRY

collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

lead

Nelson Chao

OTHER

NCT03986086 - MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter